This anti-FLT4 antibody is a Mouse Monoclonal antibody detecting FLT4 in ELISA. Suitable for Human. This Primary Antibody has been cited in 3+ publications.
FLT4
Reactivity: Human
IHC, ELISA, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/10000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Goodyear, Kheyfets, Garcia, Stearns: "Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines." in: The Prostate, Vol. 69, Issue 9, pp. 982-90, (2009) (PubMed).
Pan, Chang, Chang, Su, Wang, Hung: "Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells." in: Journal of cell science, Vol. 122, Issue Pt 18, pp. 3358-64, (2009) (PubMed).
Jayasinghe, Simiantonaki, Michel-Schmidt, Kirkpatrick: "Endothelial VEGFR-3 expression in colorectal carcinomas is associated with hematogenous metastasis." in: Oncology reports, Vol. 22, Issue 5, pp. 1093-100, (2009) (PubMed).
Target
FLT4
(Fms-Related Tyrosine Kinase 4 (FLT4))
Alternative Name
FLT4
Background
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. Tissue specificity: Placenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain. VEGFR-3 is induced in all endothelial cells (EC